127 related articles for article (PubMed ID: 33777719)
1. Data quality assessment of a South African electronic registry for drug-resistant TB, 2015-2016.
Manesen R; Mekler KA; Molobi TR; Tyiki AA; Madlavu MJ; Velen K; Charalambous S; van der Heijden YF
Public Health Action; 2021 Mar; 11(1):33-39. PubMed ID: 33777719
[TBL] [Abstract][Full Text] [Related]
2. Data quality of drug-resistant tuberculosis and antiretroviral therapy electronic registers in South Africa.
Jamieson L; Evans D; Berhanu R; Ismail N; Aucock S; Wallengren K; Long L
BMC Public Health; 2019 Dec; 19(1):1638. PubMed ID: 31805982
[TBL] [Abstract][Full Text] [Related]
3. Assessment of facility-based tuberculosis data quality in an integrated HIV/TB database in three South African districts.
Murphy JP; Kgowedi S; Coetzee L; Maluleke V; Letswalo D; Mongwenyana C; Subrayen P; Charalambous S; Mvusi L; Dlamini S; Martinson N; Moolla A; Miot J; Evans D
PLOS Glob Public Health; 2022; 2(9):e0000312. PubMed ID: 36962485
[TBL] [Abstract][Full Text] [Related]
4. Completeness and concordance of TB and HIV surveillance systems for TB-HIV co-infected patients in South Africa.
Auld SC; Kim L; Webb EK; Podewils LJ; Uys M
Int J Tuberc Lung Dis; 2013 Feb; 17(2):186-91. PubMed ID: 23317953
[TBL] [Abstract][Full Text] [Related]
5. Incremental Cost Effectiveness of Bedaquiline for the Treatment of Rifampicin-Resistant Tuberculosis in South Africa: Model-Based Analysis.
Schnippel K; Firnhaber C; Conradie F; Ndjeka N; Sinanovic E
Appl Health Econ Health Policy; 2018 Feb; 16(1):43-54. PubMed ID: 28980217
[TBL] [Abstract][Full Text] [Related]
6. Predictors of mortality and treatment success during treatment for rifampicin-resistant tuberculosis within the South African National TB Programme, 2009 to 2011: a cohort analysis of the national case register.
Schnippel K; Shearer K; Evans D; Berhanu R; Dlamini S; Ndjeka N
Int J Infect Dis; 2015 Oct; 39():89-94. PubMed ID: 26358856
[TBL] [Abstract][Full Text] [Related]
7. Effect of bedaquiline on mortality in South African patients with drug-resistant tuberculosis: a retrospective cohort study.
Schnippel K; Ndjeka N; Maartens G; Meintjes G; Master I; Ismail N; Hughes J; Ferreira H; Padanilam X; Romero R; Te Riele J; Conradie F
Lancet Respir Med; 2018 Sep; 6(9):699-706. PubMed ID: 30001994
[TBL] [Abstract][Full Text] [Related]
8. Completeness and Reliability of the Republic of South Africa National Tuberculosis (TB) Surveillance System.
Podewils LJ; Bantubani N; Bristow C; Bronner LE; Peters A; Pym A; Mametja LD
BMC Public Health; 2015 Aug; 15():765. PubMed ID: 26259599
[TBL] [Abstract][Full Text] [Related]
9. Completeness and accuracy of electronic recording of paediatric drug-resistant tuberculosis in Cape Town, South Africa.
Rose PC; Schaaf HS; du Preez K; Seddon JA; Garcia-Prats AJ; Zimri K; Dunbar R; Hesseling AC
Public Health Action; 2013 Sep; 3(3):214-9. PubMed ID: 26393032
[TBL] [Abstract][Full Text] [Related]
10. Quality of Electronic TB Register Data Compared with Paper-Based Records in the Kyrgyz Republic.
Shauer D; Petrosyan O; Gemilyan M; Kamau EM; Thekkur P; Goncharova O; Gulmira K; Kyrbashov B; Istamov K; Kadyrov M; Wilkinson E
Trop Med Infect Dis; 2023 Aug; 8(8):. PubMed ID: 37624354
[TBL] [Abstract][Full Text] [Related]
11. Impact of Xpert MTB/RIF and decentralized care on linkage to care and drug-resistant tuberculosis treatment outcomes in Johannesburg, South Africa.
Evans D; Sineke T; Schnippel K; Berhanu R; Govathson C; Black A; Long L; Rosen S
BMC Health Serv Res; 2018 Dec; 18(1):973. PubMed ID: 30558670
[TBL] [Abstract][Full Text] [Related]
12. Persistently high early mortality despite rapid diagnostics for drug-resistant tuberculosis cases in South Africa.
Schnippel K; Firnhaber C; Ndjeka N; Conradie F; Page-Shipp L; Berhanu R; Sinanovic E
Int J Tuberc Lung Dis; 2017 Oct; 21(10):1106-1111. PubMed ID: 28911353
[TBL] [Abstract][Full Text] [Related]
13. Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study.
Cox H; Dickson-Hall L; Ndjeka N; Van't Hoog A; Grant A; Cobelens F; Stevens W; Nicol M
PLoS Med; 2017 Feb; 14(2):e1002238. PubMed ID: 28222095
[TBL] [Abstract][Full Text] [Related]
14. Implementing novel regimens for drug-resistant TB in South Africa: what can the world learn?
Ndjeka N; Hughes J; Reuter A; Conradie F; Enwerem M; Ferreira H; Ismail N; Kock Y; Master I; Meintjes G; Padanilam X; Romero R; Schaaf HS; Riele JT; Maartens G
Int J Tuberc Lung Dis; 2020 Oct; 24(10):1073-1080. PubMed ID: 33126942
[TBL] [Abstract][Full Text] [Related]
15. Cost comparison of nine-month treatment regimens with 20-month standardized care for the treatment of rifampicin-resistant/multi-drug resistant tuberculosis in Nigeria.
Bada FO; Blok N; Okpokoro E; Dutt S; Akolo C; Dakum P; Abimiku A
PLoS One; 2020; 15(12):e0241065. PubMed ID: 33259492
[TBL] [Abstract][Full Text] [Related]
16. Capture-recapture to estimate completeness of tuberculosis surveillance in two communities in South Africa.
Dunbar R; van Hest R; Lawrence K; Verver S; Enarson DA; Lombard C; Beyers N; Barnes JM
Int J Tuberc Lung Dis; 2011 Aug; 15(8):1038-43. PubMed ID: 21740665
[TBL] [Abstract][Full Text] [Related]
17. Closing the reporting gap for childhood tuberculosis in South Africa: improving hospital referrals and linkages.
du Preez K; Schaaf HS; Dunbar R; Swartz A; Naidoo P; Hesseling AC
Public Health Action; 2020 Mar; 10(1):38-46. PubMed ID: 32368523
[TBL] [Abstract][Full Text] [Related]
18. A cluster-randomized controlled trial to improve the quality of integrated HIV-tuberculosis services in primary healthcareclinics in South Africa.
Gengiah S; Barker PM; Yende-Zuma N; Mbatha M; Naidoo S; Taylor M; Loveday M; Mhlongo M; Jackson C; Nunn AJ; Padayatchi N; Karim SSA; Naidoo K
J Int AIDS Soc; 2021 Sep; 24(9):e25803. PubMed ID: 34498370
[TBL] [Abstract][Full Text] [Related]
19. The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa.
Mpobela Agnarson A; Williams A; Kambili C; Mattson G; Metz L
Expert Rev Anti Infect Ther; 2020 May; 18(5):475-483. PubMed ID: 32186925
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
